Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Assessment of Everolimus in Addition to Calcineurin Inhibitors Reduction in Maintenance Renal Transplant Recipients.

Trial Profile

Assessment of Everolimus in Addition to Calcineurin Inhibitors Reduction in Maintenance Renal Transplant Recipients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2015

At a glance

  • Drugs Everolimus (Primary) ; Ciclosporin; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms ASCERTAIN
  • Sponsors Novartis
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 21 Apr 2012 Planned number of patients changed from 395 to 490 as reported by European Clinical Trials Database record.
    • 21 Jun 2011 Primary endpoint 'Glomerular-filtration-rate' has not been met, as published in Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top